VT-1161, A Novel treatment for fungal nail infection
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Fungal infection of the nails (onychomycosis) is a common condition which is hard to cure. Antifungal drugs cannot easily reach the fungus embedded in the nail, and infected nails take months to grow out. Mild cases can sometimes be treated with use of an antifungal liquid applied to the nail, but more severe infections need medicine that can reach all affected areas through the bloodstream. Even these are not always effective, and can cause side-effects such as a skin rash or liver problems, so we need something better.

A trial of their new antifungal medicine, VT-1161 is described. 259 adults with onychomycosis from 34 hospitals in the USA were recruited . Some received a dummy treatment (placebo) while the others received one of four different dosage schedules of VT-1161 for up to 22 weeks. They were followed up for a further 36 weeks without treatment.

At week 48, the cure rate in the various treatment groups ranged from 32% to 42%, compared with 0% in the placebo group. The researchers checked liver function and heart electrical recordings (electrocardiogram, ECG) and found no significant changes.

Some antifungal drugs used to treat this condition work by attacking a compound called CYP51 which is required for fungus to grow, however, this compound is also found in humans and when it attacks the compound in humans it can cause side-effects.
--VT-1161 targets fungal CYP51 2000 times more strongly than human CYP51 which should make it safer. Another advantage is that it is taken weekly rather than daily.

In conclusion, VT-1161 appears to be an effective, convenient and safe antifungal medicine.

Source: https://onlinelibrary.wiley.com/doi/10.1111/bjd.19732